Eight AIDS patients with Mycobacterium avium complex (MAC) bacteremia were randomized to receive azithromycin with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) for 6 weeks to examine the effect of GM-CSF administration on clearance of mycobacteremia and on monocyte function. Superoxide anion production was significantly increased ex vivo in monocytes from patients receiving GM-CSF but not in those from patients receiving azithromycin alone. Relative to monocytes obtained from untreated healthy controls, median differences in viable intracellular MAC at 2, 4, and 6 weeks were 00.76, 00.94, and 00.47 log 10 cfu/mL of lysate for cells from patients receiving GM-CSF versus 00.15, 00.11, and 00.19 log 10 cfu/mL for cells from patients receiving azithromycin alone. Although no effect on mycobacteremia was detected, the administration of GM-CSF to AIDS patients with MAC bacteremia resulted in activation of their blood monocytes, as evidenced by increased superoxide anion production and enhanced mycobactericidal activity. GM-CSF deserves further investigation in the treatment of mycobacterial infections.
Despite significant strides in our ability to prevent and treat agents that may enhance the ability of infected monocytes and macrophages, the usual site of residence of MAC, to suppress Mycobacterium avium complex (MAC) infections, MAC remains a significant cause of morbidity and premature mortality intracellular growth of this organism are needed. Previous studies both in vitro and in an experimental mouse model of dissemin patients with advanced human immunodeficiency virus (HIV) disease. The annual incidence of MAC infection, at least inated MAC infection have shown that the use of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) before the availability of more effective antiretroviral therapy, was Ç24% in patients with CD4 cell counts õ100/mm 3 who resulted in a significant decrease in the number of viable bacteria in macrophages, blood, liver, and spleen [6 -8] . We theredid not receive antimycobacterial prophylaxis [1, 2] . In those who do develop MAC bacteremia, optimal antimycobacterial fore evaluated the effect of GM-CSF administration to AIDS patients with MAC bacteremia in a small, randomized trial. therapy results in suppression of mycobacteremia in only Ç70%, and the risk of relapse remains high (Ç5% -60%) in patients who initially respond [3 -5] . Unfortunately, 86% -Materials and Methods 100% of those who develop recrudescent infection do so with organisms that demonstrate high-level macrolide resistance [3] .
Patients with HIV infection and newly diagnosed, previously untreated MAC bacteremia were randomized to receive orally adAdditional approaches, such as the use of immunomodulatory ministered azithromycin, 600 mg daily, with or without subcutaneously administered GM-CSF for 6 weeks. Two patients received GM-CSF in a dose-escalating fashion as follows: They first reReceived 24 June 1997; revised 11 September 1997. ceived azithromycin alone for 2 weeks, then GM-CSF at 50 mg/ to ingest neutral red. The number of monocytes in the monolayers cfu/mL, respectively. No significant difference between treatwas observed daily as previously described [6] . No preferential ment groups in the decrease in mycobacterial colony counts detachment was observed in comparisons of experimental and control groups.
could be detected in this small number of patients.
Histopaque, horse heart type III ferricytochrome c, superoxide
The study drugs were well-tolerated, and no patient required tion. The other patient complained of myalgia but continued described [6] . Macrophage monolayers (5 1 10 5 cells/well) were to receive full-dose GM-CSF. Two of 9 patients had possible infected with a dispersed suspension of M. avium strain 101 (seroreactions to azithromycin: 1 developed nausea, requiring the var 1) (5 1 10 6 cells) for 4 h, the extracellular bacteria were removed by washing, and the intracellular growth was monitored withholding of azithromycin for 1 week and then dose reducfor 4 days as previously described [10] . Monocytes from 2 healthy tion to 300 mg/day, whereas the other developed anemia, possinon-HIV-infected volunteers were used as controls for each assay.
bly related to azithromycin but more likely as a result of his After 4 days, the monolayers were lysed and the lysate was plated underlying disease.
onto Middlebrook media 7H10 as previously described [11] The mycobactericidal capacity of monocytes obtained from nificance was set at P õ .05 for the two-tailed tests.
patients with MAC bacteremia increased in 3 of the 4 subjects who received GM-CSF (figure 2), as well as in the non-MACinfected subject who received this agent. No such finding was Results observed in monocytes obtained from the patients who received azithromycin alone. At baseline, before administration of GMNine HIV-infected patients were enrolled in the study, including 8 who had MAC bacteremia and 1 who was enrolled CSF, the ability of cells to suppress intracellular growth of MAC after 4 days of incubation was not significantly different from on the basis of a report of a positive blood culture that subsequently proved erroneous. One patient was female. Five pathat of cells obtained from the 2 healthy non-HIV-infected control subjects (table 2) . However, by days 14 and 21 of study (data tients were white, 3 were Hispanic, and 1 was African American. The mean age was 35 years. The mean CD4 cell count combined), by which time 2 subjects had received 7 days of lower-dose GM-CSF (50 mg/m 2 /day) and 2 subjects had received obtained within 2 months before enrollment was 10 cells/mm 3 . Four patients were randomized to receive azithromycin alone 14 days of full-dose GM-CSF (250 mg/m 2 /day), the mean intracellular mycobacterial colony counts were 0.56 { 0.43 log 10 cfu/ and 5 were randomized to receive the combination (including the patient who was subsequently found not to have MAC mL lower in cells from the 4 GM-CSF-treated subjects than in cells from control subjects (ranging from a reduction of 0.80 to bacteremia); 2 of the latter group who were diagnosed with MAC bacteremia received their GM-CSF in a dose-escalating an increase of 0.08 log 10 cfu/mL) (P Å .40). In contrast, the mean reduction in monocyte inhibition of intracellular MAC in patients fashion. The duration of GM-CSF therapy for the 4 patients randomized to the combination ranged from 15 to 42 days who received 14 days of azithromycin alone was 0.17 { 0.17 log 10 cfu/mL relative to that of the control cells (ranging from a (median, 30). Modest increases in white blood cell counts, particularly monocyte cell numbers, were observed in patients reduction of 0.10 to 0.39 log 10 cfu/mL). A statistically significant increase in mycobacterial activity receiving GM-CSF.
Mean pretreatment MAC colony counts were, respectively, in response to GM-CSF was found by the fourth and sixth weeks of study. By day 28, the mean reduction in intracellular 0.5 { 0.6 and 1.7 { 1.6 for patients who received azithromycin / 9d43$$ap28 02-13-98 00:46:20 jinfal UC: J Infect 
NOTE. Data are median log 10 cfu/mL. * Calculated using week 4 or week 6 data (last culture obtained while patient was receiving therapy). 1 patient on each arm became culture-negative (negative cultures were designated as .099 log 10 cfu/mL, just below ability to detect presence of bacteremia).
colony counts in cells from patients receiving GM-CSF relative activity between the 2 patients who initially received the lower dosage of GM-CSF (50 mg/m 2 /day for 7 days) versus the 3 to that of control monocytes was 0.94 { 0.09 log 10 cfu/mL patients who received the higher dosage of GM-CSF (250 mg/ (range, 0.88 -1.0 log 10 cfu/mL) (P õ .001). By day 42 of study, m 2 /day for 14 days). One of the patients with MAC bacteremia the mean reduction in intracellular colony counts was 0.47 { who received the higher dosage of GM-CSF, had, in fact, a 0.09 log 10 cfu/mL (range, 0.23 -0.70 log 10 cfu/mL) (P Å .011).
modest increase in intracellular colony counts relative to norIn contrast, the mean reduction in monocyte inhibition of mal healthy control cells ( figure 3A ). intracellular MAC in those patients who received 28 and 42
One patient who was initially randomized to azithromycin days of azithromycin alone was, respectively, only 0.15 { 0.11 alone subsequently began full-dose GM-CSF therapy after the log 10 cfu/mL (ranging from a reduction of 0.07 to 0.28 log 10 cfu/ first 30 days of study (figure 3C). After 2 and 4 weeks of mL) and 0.19 { 0.27 log 10 cfu/mL (ranging from a reduction of azithromycin alone, intracellular colony counts in monocytes 0.38 to an increase of 0.01 log 10 cfu/mL) (P ú .2 for each; obtained from this subject and infected ex vivo were only 0.21 figure 3A, B) . A statistically significant difference in mycobacand 0.1 log 10 lower than that of control monocytes. However, terial activity between treatment regimens was found at day 28 after 9 days of GM-CSF therapy, intracellular colony counts of study (P Å .036).
were 0.68 log 10 lower than that of control cells (a 79% reduction). The effect of GM-CSF was seen throughout the duration of its administration. Interestingly, there was no apparent differDiscussion ence observed in the degree of monocyte antimycobacterial MAC is a facultative intracellular parasite found predominantly within cells of the monocyte-macrophage series [12] . In NOTE. Data are mean { SD (range) intracellular log 10 cfu/mL at each week of therapy (patient log 10 cfu/mL 0 control log 10 cfu/mL). Monolayers were incubated with MAC for 4 days.
* Because of pattern of dose escalation, data at day 14 and day 21 were combined; by this time 2 patients had received 7 days of lower-dose GM-CSF (50 mg/m at least one study, macrophages coinfected with HIV and MAC resultant defects in the production of cytokines, may lead to impaired monocyte function. In addition, glycopeptidolipids have been reported to exhibit both decreased viability and enhanced MAC replication [13] . The decreased number and funcderived from MAC inhibit lymphocyte proliferation, an effect that could secondarily lead to the inhibition of macrophage tion of T cells characteristic of advanced HIV disease, with Figure 3 . Ability of monocytes from patients with AIDS and MAC bacteremia receiving azithromycin in combination with GM-CSF (A), azithromycin alone (B), or azithromycin followed by GM-CSF therapy after 30 days (C) to suppress intracellular growth of MAC strain 101 ex vivo relative to that of monocytes from untreated normal controls. In A, solid line indicates intracellular suppression of MAC in monocytes obtained from 1 patient who had AIDS but did not have MAC bacteremia and who received GM-CSF. In C, after administration of GM-CSF for 9 days, intracellular replication of MAC was reduced by 79% relative to that of control monocytes.
/ 9d43$$ap28 02-13-98 00:46:20 jinfal UC: J Infect activation [14] . It has also been reported that an inhibitor of On the other hand, administration of this cytokine had no effect on mycobacteremia in a small number of AIDS patients with intracellular MAC growth, present in the serum of HIV-infected patients without AIDS as well as non -HIV-infected disseminated MAC infection [31] . Azithromycin has been demonstrated to have efficacy in the persons, is absent in AIDS patients [15, 16] .
The mechanism by which monocytes/macrophages inhibit treatment of disseminated MAC infection in AIDS patients [32, 33] . In one study, MAC colony counts fell 1.55 -2.0 log 10 , and the growth of intracellular MAC remains uncertain, since the production of neither reactive oxygen nor nitrogen intermedisterilization of blood cultures occurred in 42% -56% of patients who received up to 6 weeks of azithromycin as a single agent ates is responsible [17] . Phagosome and lysosome fusion appears to be impaired, and the undamaged organism proliferates (600 -1200 mg/day) [33] . Nonetheless, recrudescent mycobacteremia, associated with high-level macrolide resistance in within the mycobacterial vacuole, which fails to acidify as a result of exclusion of the vesicular proton ATPase [18, 19] .
vitro, may occur within 16 weeks in a majority of patients receiving macrolide monotherapy [34] . For this reason, macroIt has been suggested that the bacteriostasis associated with exposure to cytokines, such as interferon (IFN)-g, tumor necrolide monotherapy is not recommended. Although the optimal antimycobacterial regimen for the treatment of MAC bactersis factor (TNF)-a, and GM-CSF, is the result of acidification of the phagosome [20] .
emia in AIDS has not been determined, the combination of clarithromycin and ethambutol has been central to the most In vitro studies indicate that the activity of cytokines, such as TNF-a and GM-CSF, is, in fact, critical to the ability of effective (i.e., most durable) combination regimens studied to date [3 -5] . Whether a third agent -and which of the remaining monocytes to restrict MAC replication. GM-CSF activates human monocytes to inhibit intracellular MAC, whether it is agents -can enhance the durability of the response has not been determined, although clofazimine no longer appears to added to the in vitro system before or after infection [6, 21] . The addition of TNF-a enhances the anti-MAC effect of GMbe a viable third choice, and its use may be associated with increased mortality [5] . CSF, while IFN-g antagonizes it. GM-CSF and TNF-a each cause inhibition of intracellular growth of MAC within human Azithromycin achieves high concentrations within phagocytic cells, especially within acidic vacuoles, as a result of its alveolar macrophages, while both interleukin-2 and IFN-g are ineffective [22] . The inhibition of growth of MAC within macdibasic amphophilic structure [35] . The pH of the mycobacterial vacuole (pH 6.9 -8.6) may therefore result in lack of rophages mediated by vitamin D 3 is dependent on the activity of either TNF or GM-CSF [23] .
azithromycin accumulation at this critical site, as is the case with Toxoplasma gondii -infected cells [36] . The proposed The administration of GM-CSF to patients with fungal infections and malignancies results not only in increased peripheral acidification of the mycobacterial vacuole by GM-CSF may therefore result in increased accumulation of the azalide at this blood leukocyte concentration but also in functional alterations of those cells [24, 25, 25a] . Administration of GM-CSF at 250 site. Acidification, unfortunately, also reduces the antibacterial activity of azithromycin [37, 38] . Nonetheless, in vitro and mg/m 2 /day by continuous infusion to patients with refractory testicular cancer receiving autologous bone marrow transin vivo studies using the beige mouse demonstrate that the combination of GM-CSF with either azithromycin or amikacin plantation resulted in increased monocyte major histocompatibility complex class I and II expression, as well as increased resulted in greater anti-MAC effect than seen with any of these compounds used alone [7, 39] . Furthermore, with the exception ex vivo monocyte-mediated cytotoxicity against U937 tumor cells [26]. We recently reported that GM-CSF administration to of roxithromycin, the macrolide antibiotics can function as immunomodulators by stimulating phagocytosis, macrophage a non -HIV-infected patient with disseminated Mycobacterium kansasii infection who had abnormal monocyte function rechemotaxis, and cytocidal activity, at least against certain organisms, such as Candida albicans [40] . Liposome-associated sulted in activation and enhanced mycobactericidal activity of those cells studied ex vivo [27] . The administration of GM-GM-CSF is more potent than free GM-CSF against MAC residing within human monocyte-derived macrophages, and the ad-CSF, 300 mg three times weekly for 4 weeks, appeared to result in the reduction of abscesses due to Blastoschizomyces dition of GM-CSF significantly augments the activity of azithromycin compared with the effects of the agents alone capitatus infection in a patient with acute myeloid leukemia [28] . Its use is, however, probably limited by the need for [41] . We report here that administration of GM-CSF to AIDS parenteral administration and the potential for dose-related toxicity, although the drug was tolerated in this study. Lower patients with disseminated MAC bacteremia also receiving azithromycin results in activation of their monocytes, as redosages of GM-CSF, which may be better tolerated, appeared to result in ex vivo activity comparable to that achieved by the flected ex vivo in increased oxidative burst, and more important, increased mycobactericidal activity. We were unable, later larger dosages in the 2 patients who underwent escalation of their dosages.
however, to demonstrate a statistically significant mycobactericidal effect in vivo in this small short-term study. Such an Therapy with other cytokines, alone or in combination, may also be worthy of exploration [29] . IFN-g administration to effect may have been masked by the potent anti-MAC effect of azithromycin. It is possible that a larger, more prolonged members of a family with disseminated MAC infection in the absence of HIV infection was therapeutically successful [30] . study evaluating the effect of GM-CSF, particularly in a cir-/ 9d43$$ap28 02-13-98 00:46:20 jinfal UC: J Infect
